Deletion of Setd2 affects the myeloid differentiation and cell cycle in the NHD13 mouse model. (A-B) Representative flow cytometry profiles (A) and quantification of the cells counts and frequencies (B) of the GMP, MEP, and CMP cells of the mice receiving NHD13/Setd2^f/f or Mx1-Cre/NHD13/Setd2^f/f BM cells. (C-D) Representative flow cytometry profiles (C) and quantification of the frequencies (D) of the PB, BM, and spleen cells of the WT, NHD13/Setd2^f/f, and NHD13/Setd2^Δ/Δ mice at the indicated erythroid differentiation stages (RI, proerythroblasts; RII, basophilic erythroblasts; RII, chromatophilic erythroblasts; RIV, orthochromatophilic erythroblasts). (E) CFU assays analyzing the HSPCs isolated from the mice receiving NHD13/Setd2^f/f or Mx1-Cre/NHD13/Setd2^f/f BM cells. The representative images of CFUs are shown. Cells (3 × 10³) were plated for each assay. (F) Quantification of the number of colonies of burst-forming unit-erythroid (BFU-E), colony-forming unit-granulocyte (CFU-G), colony-forming unit-macrophage (CFU-M), and colony-forming unit-granulocyte, macrophage (CFU-GM) cells. (G) Representative flow cytometry results of the BrdU incorporation assay and (H) quantification of the frequencies of the BM Lin⁻ cells of the NHD13/Setd2^f/f or NHD13/Setd2^Δ/Δ mice at the indicated cell cycle stages. The cells were collected at 4 weeks after poly(I:C) injection. *P < .05; **P < .01; ***P < .001; ****P < .0001.